Methadone News and Research

RSS

AAPM commends FDA’s move to introduce labeling changes on ER/LA opioids

The physicians of the American Academy of Pain Medicine (AAPM) hailed long-awaited labeling changes and other steps taken by the U.S. Food and Drug Administration (FDA) last week to enhance safety in the prescribing of extended-release and long-acting (ER/LA) opioids.

18 Sep 2013

Relmada Therapeutics collaborates with the Malvern Consulting Group

Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that has signed a collaboration agreement with the Malvern Consulting Group as clinical and regulatory advisor.

16 Sep 2013

Relmada Therapeutics reports positive results from pivotal pharmacokinetic study of LevoCap ER

Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.

10 Sep 2013

Expansion of heroin, opioid medical treatment needed to reduce overdose deaths

A new report from Simon Fraser University researcher Bohdan Nosyk calls for the expansion of heroin and opioid medical treatment to stem the increase of overdose deaths.

7 Aug 2013

Combination treatment can reduce hepatitis C infection in people who inject drugs

The burden of liver disease could be dramatically reduced by scaling up the combination of interventions for hepatitis C infection among people who inject drugs according to University of Bristol researchers. The findings, published today [24 July], form part of new global recommendations on treating the virus.

25 Jul 2013

New Mexico Medicaid overhaul OK'd

Medicaid recipients will face co-pays for some treatments and have their medical services tracked as part of a program overhaul that is intended to lower the costs of providing health care, Gov. Susana Martinez's administration announced Monday. There will be no changes in determining who qualifies for Medicaid, which serves about a quarter of New Mexico's population (Massey, 7/15).

16 Jul 2013

Ritalin helps improve brain function in cocaine addiction

A single dose of a commonly-prescribed attention deficit hyperactivity disorder drug helps improve brain function in cocaine addiction, according to an imaging study conducted by researchers from the Icahn School of Medicine at Mount Sinai.

28 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

Correctional policies discourage released inmates from seeking methadone therapy, researchers say

Methadone treatment for opioid dependence remains widely unavailable behind bars in the United States, and many inmates are forced to discontinue this evidence-based therapy, which lessens painful withdrawal symptoms.

30 Mar 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

Annual deaths related to heroin and morphine continue to drop in the UK

Annual deaths related to heroin and morphine are continuing to drop significantly, falling from 41 per cent of total drug-related deaths in the UK in 2010 to 32 per cent in 2011. Meanwhile, deaths from 'legal highs' - some of which have now been banned - remained steady following a large increase in the previous year.

28 Feb 2013

Education and response programs reduce opioid overdose deaths

Results from a US study suggest that a state-supported program of overdose education and nasal naloxone distribution for potential bystanders can help reduce opioid-related overdose deaths.

8 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013

Longer looks: A key Hagel mission is to cut military health costs; Medical lessons from a mother's death; How they price - and how we pay for -a $300,000 medicine

As David Brooks and Paul Wolfowitz and many others have shown, it's easy to frame our messy fiscal conundrum in these simple terms of guns vs. butter, or rather, guns vs grandma's buttery-yellow, super-pricey heart medication.

11 Jan 2013

European health officials warn Greece to address increasing number of HIV cases

Officials with the European Centre for Disease Prevention and Control (ECDC) said Greece must act to combat a rising number of HIV cases within high-risk populations, including drug users, or face increased health care costs in the future, Reuters reports.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.